Registration process for generic drugs shortened

THE Food and Drug Administration (FDA) on Friday said it will shorten the period of registration, evaluation and approval of generic drugs, following the directive of President Ferdinand Marcos Jr. to ensure safe and accessible essential drugs.

With the help of the Center for Drug Regulation and Research, the FDA on Thursday issued a Facilitated Review Pathway through an FDA Circular, which aims to provide an alternative process to those who wish to register generic drugs in the country.